News Feed Item

Lombard Medical Technologies PLC: Pre-Close Trading and Strategic Update

LONDON, UK -- (Marketwired) -- 01/08/14 --

                   Lombard Medical Technologies PLC
                 ("Lombard Medical" or "the Company")

                Pre-Close Trading and Strategic Update

         Global AorfixTM growth; US rollout progressing well
  Intention to pursue a US IPO and NASDAQ listing of ordinary shares

London, UK and Irvine, CA, 8 January, 2014 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic
aneurysms ("AAAs"), announced today a pre-close trading update for the
financial year ended 31 December 2013 as well as a strategic update.
All figures are unaudited.

Trading Update

AorfixTM commercial revenue grew 25% to GBP3.9m with revenue from the
main EU markets growing 9%. Revenue from the Rest of World ("ROW")
markets grew 28% and the US contributed to fourth quarter Aorfix
commercial revenue growth of 38% following formal launch in November.
In Europe, the Company experienced strong demand and revenue growth in
Germany and Spain. Following consolidation of EVAR centers in the UK,
which negatively impacted UK revenue in the first half of 2013, second
half 2013 Aorfix revenue in the UK recovered and was flat compared to
the same period the previous year. Total Company revenue grew by 14% to
GBP4.5m, reflecting a decline in revenue of the recently divested OEM
business in Scotland which fell by 27% compared to last year. As
previously announced, this business was divested on 20 December 2013.

Aorfix was approved by the United States Food and Drug Administration
("US FDA") in February 2013 with a unique label indication for the
treatment of patients with angulations at the neck of the aneurysm up
to and including 90 degrees. The product was formally launched in the
US, the largest EVAR market, at the 40th Annual VEITH Symposium, in New
York in November. While Aorfix is still in the initial phase of the US
launch, the product rollout is progressing well, with the number of US
physicians trained to use the device standing at 244 at the year end.
As previously disclosed, the Company's 20-person sales team is
targeting around 300 high volume EVAR centers that perform more than
half of the EVAR procedures in the US.

In Japan, the Company now anticipates regulatory approval for Aorfix
during 2014. Our exclusive Japanese marketing partner, Medico's
Hirata, remains in dialogue with the Pharmaceuticals and Medical
Devices Agency (PMDA) to achieve this. Medico's Hirata is a leading
supplier of medical device products in Japan, with the sales
infrastructure to realize the potential of Aorfix in this growing
market, which in 2013 was estimated to account for approximately $140m
or 10% of the global EVAR market.

As previously announced, the Company is expanding its manufacturing
facility in Didcot, Oxfordshire, to support increasing global demand
for Aorfix. The expansion, which involves the construction of a new
cleanroom and materials handling space, will add around 10,000 sq. ft.
to the existing facility. The expansion project is expected to be
completed by the end of the first quarter of 2014.

The global AAA market for EVAR devices is estimated to be approximately
$1.4bn. The US market is estimated to be worth around half of the
global market and is expected to grow at a compound annual growth rate
in excess of 7% over the next 5 years, driven largely by the growth of
the ageing population and patient screening programs. In addition,
introduction of new technologies such as Aorfix, which allow more
patients to received endovascular treatment of AAA disease, could
potentially further expand the market.

The Company closed 2013 with cash of GBP24.8m and debt of GBP1.5m on its
balance sheet.


As announced today in a separate press release, the Company intends to
submit a registration statement to the US Securities and Exchange
Commission ("SEC") relating to a proposed US initial public offering of
ordinary shares and a listing on NASDAQ ("NASDAQ IPO").

To facilitate the NASDAQ IPO, a new Cayman Islands holding company will
be created and existing shares in Lombard Medical will be exchanged for
new shares in that holding company ("Share Exchange")

Commencement of the initial public offering is conditional upon
completion of the SEC review process with respect to the registration
statement and is subject to market conditions and other
considerations. In connection with the NASDAQ IPO, Lombard Medical
will also delist its ordinary shares from AIM, a market of the London
Stock Exchange.

In the Share Exchange, existing shareholders will receive shares in the
new Cayman Islands holding company in exchange for the shares they hold
in Lombard Medical. These new shares will not be admitted to trading on
AIM. Shareholders will need to consider their ability to hold and trade
NASDAQ listed shares following the Share Exchange and the AIM
delisting. Full details of the proposals will be set out in a circular
to shareholders in due course.

Lombard Medical intends to use proceeds from the NASDAQ IPO to
accelerate its commercialization strategy for Aorfix in the US with a
particular focus on continuing to expand its direct sales force to
accelerate penetration of the US AAA market. The Company will also
continue to invest in developing new products to treat complex vascular
disease, including a stent graft to treat aneurysms in the thoracic

This press release does not constitute an offer of any securities for


For further information:

Lombard Medical Technologies PLC              Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer

Canaccord Genuity Limited                     Tel: +44 (0)20 7523 8000
Lucy Tilley / Tim Redfern /
Henry Fitzgerald O'Connor / Dr Julian Feneley

FTI Consulting (UK)                           Tel: +44 (0)20 7831 3113
Simon Conway / Stephanie Cuthbert /
Victoria Foster Mitchell

Allen & Caron (US)                            Tel: +1 (949) 474 4300
Matt Clawson

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year over
500,000 new cases are diagnosed. In the US, aortic aneurysm disease is
among the leading causes of death and it is estimated that 1.7 million
people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.4 billion per annum abdominal
aortic aneurysm ("AAA") repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. Aorfix is the
only stent graft approved for AAA neck angulations of up to 90 degrees
and is currently being commercialized worldwide. Aorfix is the first
AAA stent graft not of US origin to gain US FDA approval. The Company
is headquartered in Oxfordshire, England with US operations in Irvine,

Further background on the Company can be found at


This announcement may contain forward-looking statements that reflect
the Company's current expectations regarding future events, including
the commercialization and regulatory clearance of the Company's
products, the Group's liquidity and results of operations, as well as
the Group's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of
factors, including the success of the Company's research and
development and commercialization strategies, the uncertainties related
to the regulatory process and the acceptance of the Company's products
by hospitals and other medical professionals.

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
DXWorldEXPO LLC announced today that "Miami Blockchain Event by FinTechEXPO" has announced that its Call for Papers is now open. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expe...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.